Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CASR | P41180 | 10/20 | 0.55 |
| ▸ | SIGMAR1 | Q99720 | 2/20 | 0.51 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.51 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.51 |
| ▸ | PLAAT3 | P53816 | 1/20 | 0.48 |
| ▸ | PLAAT5 | Q96KN8 | 1/20 | 0.48 |
| ▸ | PLAAT2 | Q9NWW9 | 1/20 | 0.48 |
| ▸ | PLAAT4 | Q9UL19 | 1/20 | 0.48 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.47 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5519885 | 0.96 | CASR (0.56) | CASRSIGMAR1TDP1L3MBTL1PLAAT3 | |
| SCHEMBL5527612 | 0.90 | CASR (0.59) | CASRPLAAT3PLAAT5PLAAT2PLAAT4 | |
| SCHEMBL5521284 | 0.85 | CASR (0.64) | CASRL3MBTL1 | |
| SCHEMBL6439235 | 0.83 | CASR (0.65) | CASRALDH1A1 | |
| Hydrochloric Acid SCHEMBL27510065 | 0.82 | CASR (0.49) | CASR | |
| Hydrochloric Acid SCHEMBL5512676 | 0.82 | CASR (0.64) | CASRALDH1A1 | |
| SCHEMBL5516663 | 0.81 | CASR (0.58) | CASRALDH1A1 | |
| SCHEMBL5524136 | 0.80 | CASR (0.76) | CASRTDP1L3MBTL1 | |
| SCHEMBL5511591 | 0.79 | CASR (0.74) | CASRTDP1L3MBTL1 | |
| SCHEMBL14383063 | 0.79 | CASR (0.70) | CASR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20070249702-A1 | CALCILYTIC COMPOUNDS | GLAXOSMITHKLINE LLC | 2007-10-25 | — | — | US | disclosed |
| US-7202261-B2 | Calcilytic compounds | NPS PHARMACEUTICALS, INC. (US) | 2007-04-10 | — | — | US | disclosed |
| EP-0901459-B1 | CALCILYTIC COMPOUNDS | NPS PHARMA INC (US) | 2005-06-29 | — | — | EP | disclosed |
| US-20050032850-A1 | Calcilytic compounds | NPS PHARMACEUTICALS, INC. | 2005-02-10 | — | — | US | disclosed |
| US-6818660-B2 | FOR INHIBITING CALCIUM RECEPTOR ACTIVIT; TO STIMULATE SECRETION OF PARATHYROID HORMONE (PTH); FOR BONE FORMATION | NPS PHARMACEUTICALS, INC. | 2004-11-16 | — | — | US | disclosed |
| US-6521667-B1 | Calcilytic compounds | NPS PHARMACEUTICALS, INC. | 2003-02-18 | — | — | US | disclosed |
| US-6432656-B1 | Calcilytic compounds | NPS PHARMACEUTICALS, INC. | 2002-08-13 | — | — | US | disclosed |
| US-20020099220-A1 | Calcilytic compounds | NPS PHARMACEUTICALS, INC. | 2002-07-25 | — | — | US | disclosed |
| US-6022894-A | Method of using calcilytic compounds | NPS PHARMACEUTICALS, INC. (US) | 2000-02-08 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050032850-A1 | Calcilytic compounds | CALCR, CASR, ORAI1 | CASR 2/4885SIGMAR1 2059/4885TDP1 4759/4885 |
| US-20070249702-A1 | CALCILYTIC COMPOUNDS | CALCR, CASR, ORAI1 | CASR 2/4885SIGMAR1 2059/4885TDP1 4759/4885 |
| US-20020099220-A1 | Calcilytic compounds | CALCR, CASR, CALCRL | CASR 2/4885SIGMAR1 1890/4885TDP1 4636/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.